Dr. Maloney Discusses Excitement With CAR T-Cell Therapy

David G. Maloney, MD, PhD
Published: Wednesday, Oct 18, 2017



David G. Maloney, MD, PhD, member of the Clinical Research Division, Fred Hutchinson Cancer Research Center, Washington, discusses excitement with chimeric antigen receptor (CAR) T-cell therapy.

With the recent FDA approval of tisagenlecleucel (Kymriah) in acute lymphocytic leukemia (ALL), there has been a lot of buzz about CAR T cell-therapy in hematologic malignancies.
 
SELECTED
LANGUAGE


David G. Maloney, MD, PhD, member of the Clinical Research Division, Fred Hutchinson Cancer Research Center, Washington, discusses excitement with chimeric antigen receptor (CAR) T-cell therapy.

With the recent FDA approval of tisagenlecleucel (Kymriah) in acute lymphocytic leukemia (ALL), there has been a lot of buzz about CAR T cell-therapy in hematologic malignancies.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Current Status and the Future Potential of CAR T-Cell Therapy for Lymphoid Malignancies: The Experts Weigh-In on Recent Data and Clinical ExperienceJan 31, 20192.0
Community Practice Connections: Precision Medicine Through Plasma: Using Liquid Biopsies in Contemporary Oncology CareJan 31, 20191.5
Publication Bottom Border
Border Publication
x